8-K: iCAD Pre-Announces Estimated Q4 2024 Revenue, Reports 11% Growth in Annual Recurring Revenue

iCAD reports preliminary unaudited Q4 2024 revenue between $5.1 and $5.3 million and an 11% year-over-year increase in Total Annual Recurring Revenue.

Summary

• iCAD has released preliminary, unaudited financial results for the fourth quarter of 2024.
• The company expects total revenue for the quarter to be between approximately $5.1 and $5.3 million.
• Total Annual Recurring Revenue (T-ARR) reached approximately $9.8 million, marking an 11% increase year-over-year.
• iCAD closed 106 deals in Q4 2024, with 19 of those being cloud-based deals.
• The company will participate in the BTIG at Snowbird conference in February 2025.
• Full audited financial results for Q4 and the year ended December 31, 2024, will be announced in March 2025.
• The preliminary financial information is based on management's estimates and is subject to change.

Sentiment

Score: 7

Explanation: The document presents a positive outlook with strong recurring revenue growth and new cloud deals, but the preliminary nature of the results and the lack of full audited financials temper the overall sentiment.

Positives

• The company experienced an 11% year-over-year growth in Total Annual Recurring Revenue, indicating a strong recurring revenue base.
• iCAD closed a significant number of deals in Q4 2024, including a notable number of cloud-based deals, suggesting a growing adoption of their cloud solutions.
• The company's participation in the BTIG conference provides an opportunity to engage with investors.

Negatives

• The financial results are preliminary and unaudited, and the final results may differ materially from these estimates.
• The company's full financial statements for the year ended December 31, 2024, are not yet available, creating some uncertainty.

Risks

• The preliminary financial information is based on management's estimates and is subject to change.
• The final consolidated financial results may differ materially from the estimates provided.
• The company's future performance is subject to various risks, including market acceptance of their products, competition, and regulatory changes.
• There are risks related to the company's ability to achieve business and strategic objectives, and the willingness of patients to undergo mammography screening.

Future Outlook

The company anticipates announcing full audited financial results for Q4 and the year ended December 31, 2024, in March 2025. iCAD also plans to continue expanding access to its products and improving performance.

Management Comments

• Dana Brown, Chief Executive Officer, and Eric Lonnqvist, Chief Financial Officer, will participate in one-on-one meetings with investors at the BTIG conference.

Industry Context

This announcement is relevant to the medical technology and digital health sectors, particularly companies focused on AI-powered cancer detection solutions. The growth in recurring revenue and cloud deals indicates a trend towards subscription-based models and digital transformation in healthcare.

Comparison to Industry Standards

• iCAD's 11% year-over-year growth in Total Annual Recurring Revenue is a positive sign, especially when compared to other medical technology companies in the diagnostic space.
• Companies like Hologic and Exact Sciences, which also focus on cancer diagnostics, have seen varying growth rates, making iCAD's performance noteworthy.
• The shift towards cloud-based solutions is a common trend in the industry, and iCAD's 19 cloud deals in Q4 align with this movement.
• However, without full audited results, it's difficult to make a complete comparison to industry benchmarks.

Stakeholder Impact

• Shareholders will be interested in the revenue growth and recurring revenue figures.
• Customers will be impacted by the availability of iCAD's AI-powered solutions.
• Employees will be affected by the company's overall performance and growth.

Next Steps

• iCAD will participate in the BTIG at Snowbird conference in February 2025.
• The company will announce full audited financial results for Q4 and the year ended December 31, 2024, in March 2025.

Key Dates

Keywords

iCAD, AI, Breast Health, Mammography, Recurring Revenue, Cloud Deals, MedTech, Financial Results, Cancer Detection, ProFound AI